BioRevolution Selects BREV-100 as Lead Development Candidate to Build Muscle Mass and Strength
Redwood City, CA, Oct. 15, 2025 – BioRevolution, a next-generation biotech company dedicated to building, restoring, and preserving muscle mass and strength for longevity, today announced the selection of BREV-100 as its lead development candidate to restore muscle mass and strength. The initial focus for BREV-100 is in Pompe disease, a rare genetic disorder characterized by progressive muscle weakness due to glycogen accumulation. The company will continue to validate additional indications for BREV-100, leveraging the broad potential of its mechanism of action including Obesity and Sarcopenia.
BREV-100 is a first-in-class, oral small molecule designed to target the glycogen degradation pathway, harnessing the body’s central mechanism for building functional muscle and mimicking the adaptive signals of intense resistance training. By addressing the underlying glycogen accumulation in patients with Pompe, BREV-100 has the potential to restore muscle function and improve quality of life for people living with this debilitating disease.
“Selecting BREV-100 as our lead development candidate represents a major milestone in advancing our mission to transform muscle biology and treat debilitating muscle wasting diseases,” said Thomas Butler, Chief Executive Officer. “We are excited to advance with IND-enabling studies and prepare for clinical development, with the goal of delivering a novel therapy for people living with Pompe disease.”
About BioRevolution:
BioRevolution is a biopharmaceutical company dedicated to building, restoring, and preserving muscle mass and strength for Longevity. Our approach harnesses the body’s natural, evolutionary mechanism of building functional muscle with broad applicability across multiple muscle wasting diseases, including Glycogen Storage Disorders, Muscular Dystrophies, Obesity, and Sarcopenia.
The company’s lead program, BREV-100, is a first-in-class, oral small molecule that targets the glycogen degradation pathway to activate the body’s central mechanism of building functional skeletal muscle starting with Pompe disease, where excess glycogen drives progressive muscle impairment.
BioRevolution is led by a seasoned team that has advanced multiple innovative therapies into the clinic and is united by a mission to transform muscle biology and extend healthy human lifespan for millions of patients living with rare and chronic diseases.
Company Contact:
info@biorevolutiontx.com
